We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Advice for Patients |

Pertussis and the DTaP Vaccine FREE

Arch Pediatr Adolesc Med. 2009;163(5):496. doi:10.1001/archpediatrics.2009.62.
Text Size: A A A
Published online

Pertussis, also known as whooping cough, is a very contagious respiratory tract infection caused by a bacterium called Bordetella pertussis. It can infect people of any age, but the infection can be very serious in infants. Complications of a pertussis infection in infants include pneumonia, seizures, brain injury, and death.


The pertussis vaccine (also called an immunization) has been in common use since the 1940s. When the pertussis part of the vaccine was combined with diphtheria (D) and tetanus (T) vaccines, it was called DTP. Side effects of the vaccine were usually caused by the “P” or pertussis part of the vaccine. Side effects were most commonly soreness at the injection site, fever, and fussiness. These side effects are not unusual for vaccines. However, concerns about these side effects led some parents to refuse this vaccine. In the 1980s, pertussis infections began to increase.

A few years ago, a new vaccine became available called DTaP. The “a” stands for “acellular”; this means that this vaccine does not contain the whole pertussis bacteria cell. The DTaP vaccine contains only the parts of the bacterial cell needed to help your body fight against pertussis bacteria. Neither the DTP nor the DTaP vaccine ever contained live bacteria. The DTaP vaccine is considered safer and has fewer side effects than the older DTP vaccine.

There is also a new vaccine, licensed in 2005, called Tdap. It has a full concentration of tetanus (T) and lower concentrations of diphtheria (d) and acellular pertussis (ap). It is recommended as a one time–only vaccine for adolescents.


For maximum protection against pertussis, all children need 5 DTaP shots. DTaP shots should be given at ages:

  • •  2 months

  • •  4 months

  • •  6 months

  • •  15 to 18 months

  • •  4 to 6 years

A Tdap shot should be given once between the ages of 11 and 18 years.

A research study in this month's Archives looked at a “minimum interval DTaP schedule.” This means an immunization schedule with only 4 weeks in between the first 3 vaccines instead of the usual 8 weeks. The researchers studied a large outbreak of pertussis in which many people became infected very quickly. They found that this minimum interval schedule could protect young infants from pertussis in cases of a large outbreak of the infection. This schedule could also be useful to help protect infants if the baby is behind schedule on immunizations and needs to get protection from pertussis as quickly as possible.


The Centers for Disease Control (CDC), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP) all recommend this vaccine.




To find this and other Advice for Patients articles, go to the Advice for Patients link on the Archives of Pediatrics and Adolescent Medicine Web site at http://www.archpediatrics.com.

Box Section Ref ID

The Advice for Patients feature is a public service of Archives of Pediatrics and Adolescent Medicine. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your child's medical condition, Archives of Pediatrics and Adolescent Medicine suggests that you consult your child's physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles